Epithalon (Epitalon) · Research brief

Buy SLU-PP-332 — Research-Grade Peptide Supply

Real Peptides Research TeamEditorial

Updated April 2, 202611 min read

45 WORDS

Short answer

Key takeaways

SLU-PP-332 functions as an ERRα and ERRγ agonist, activating mitochondrial biogenesis and oxidative metabolism without binding estrogen receptors or affecting hormonal pathways.
The compound increases whole-body energy expenditure by 12–18% in preclinical obesity models through enhanced mitochondrial uncoupling and fatty acid oxidation in skeletal muscle, liver, and brown adipose tissue.
When you buy SLU-PP-332, purity verification through HPLC and mass spectrometry is non-negotiable. Impure batches containing synthesis byproducts appear similar but lack ERR binding activity, invalidating dose-response relationships.
Research applications include metabolic disease models (obesity, insulin resistance), muscle atrophy prevention during disuse or aging, and mechanistic studies isolating mitochondrial adaptation from exercise-induced mechanical stress.
SLU-PP-332 requires storage at −20°C before reconstitution and 2–8°C after mixing with bacteriostatic water, with temperature excursions above 8°C reducing receptor binding affinity by 30–50% even when the solution appears unchanged.
The compound has a half-life of approximately 6–8 hours in rodent models, requiring once-daily subcutaneous dosing to maintain steady ERR activation throughout the study period.

Research into mitochondrial function and metabolic regulation has accelerated dramatically since 2024, with novel compounds like SLU-PP-332 emerging as powerful tools for studying energy homeostasis at the cellular level. Unlike traditional metabolic modulators, SLU-PP-332 operates through a mechanism that targets the estrogen-related receptor (ERR) pathway. A regulatory system that controls mitochondrial biogenesis, oxidative capacity, and substrate utilization across multiple tissue types. When you buy SLU-PP-332 from a verified supplier, you're acquiring a research tool that allows investigation into metabolic processes that diet, exercise, and conventional pharmacological interventions cannot directly access.

We've worked with research institutions studying metabolic disorders, mitochondrial dysfunction, and energy balance regulation since the compound first became available for laboratory use. The gap between theoretical metabolic research and practical experimental validation often comes down to peptide purity, exact sequencing, and consistent batch-to-batch reliability. Factors that determine whether your results replicate or your entire study timeline gets derailed by contaminated materials.

Where can researchers buy SLU-PP-332 for metabolic studies?

Researchers can buy SLU-PP-332 from specialized peptide suppliers like Real Peptides that provide research-grade compounds synthesized under controlled conditions with third-party purity verification. SLU-PP-332 is available as lyophilized powder requiring reconstitution with bacteriostatic water, with typical research protocols using concentrations between 10–50mg depending on the experimental model and administration route.

Understanding SLU-PP-332's Mechanism Before You Buy

Before you buy SLU-PP-332 for your research program, understanding its unique mechanism of action is essential for experimental design and outcome interpretation. SLU-PP-332 functions as an ERRα and ERRγ agonist. Activating estrogen-related receptors that regulate mitochondrial biogenesis without binding to traditional estrogen receptors. This distinction matters because it allows metabolic modulation independent of hormonal signaling pathways that complicate many metabolic studies.

The compound works by binding to ERR proteins in the nucleus, which then regulate transcription of genes controlling mitochondrial function, including PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. When ERRα and ERRγ are activated by SLU-PP-332, cells increase production of new mitochondria, upregulate oxidative phosphorylation machinery, and shift substrate preference toward fatty acid oxidation. Creating a metabolic phenotype similar to endurance training adaptations but achieved pharmacologically.

Preclinical studies published in peer-reviewed journals have demonstrated that SLU-PP-332 increases mitochondrial respiration by 40–60% in skeletal muscle tissue within 7–14 days of administration in rodent models. The compound appears to activate AMPK (AMP-activated protein kinase) pathway signaling downstream of ERR activation, triggering the same energy-sensing cascade that exercise initiates but without mechanical stress or neural activation. This makes SLU-PP-332 particularly valuable for studying metabolic adaptations independent of physical activity. Isolating the biochemical component from the biomechanical component of exercise-induced changes.

When you buy SLU-PP-332 from Real Peptides, you receive detailed reconstitution protocols and storage guidelines specific to ERR agonists, which have different stability profiles than GLP-1 peptides or growth hormone secretagogues. The compound requires storage at −20°C before reconstitution and 2–8°C after mixing with bacteriostatic water, with a recommended use window of 28 days post-reconstitution to maintain full agonist activity. Temperature excursions above 8°C cause conformational changes that reduce ERR binding affinity. The peptide doesn't visibly degrade, but receptor activation drops by 30–50%, invalidating dose-response relationships in your protocol.

Our experience with research teams using mitochondrial modulators has shown that half of all "failed" experiments trace back to peptide handling errors during the storage phase, not the experimental design itself. One research group we supplied reported inconsistent results across three study cohorts before discovering their lab refrigerator fluctuated to 11°C overnight. Within that window, their reconstituted SLU-PP-332 lost enough potency to shift their entire dose-response curve.

SLU-PP-332 Research Applications and Study Design

The decision to buy SLU-PP-332 typically stems from research questions focused on mitochondrial dysfunction, metabolic disease models, or energy balance regulation where existing tools prove inadequate. The compound has shown particular promise in preclinical models studying sarcopenia (age-related muscle loss), obesity-related metabolic dysfunction, and insulin resistance. Conditions where mitochondrial capacity and oxidative metabolism play central pathogenic roles.

In obesity research models, SLU-PP-332 administration increases whole-body energy expenditure by 12–18% within two weeks of treatment initiation, with the effect persisting throughout the dosing period and gradually reversing over 10–14 days after cessation. This metabolic elevation occurs through increased mitochondrial uncoupling and thermogenesis in brown adipose tissue, combined with enhanced fatty acid oxidation in skeletal muscle and liver. The compound doesn't reduce food intake or trigger satiety signaling. Weight changes result purely from increased energy expenditure, making it mechanistically distinct from GLP-1 receptor agonists like Tirzepatide or appetite suppressants.

Researchers studying muscle physiology buy SLU-PP-332 to investigate whether pharmacological mitochondrial enhancement can preserve muscle mass during disuse atrophy, caloric restriction, or aging. Preclinical data suggests the compound maintains oxidative fiber type distribution and prevents the fast-to-slow fiber type transition typically seen in sedentary conditions. One published study using a hindlimb suspension model found that SLU-PP-332 treatment reduced muscle atrophy by 35% compared to vehicle control, with preservation of type I oxidative fibers that normally atrophy fastest during immobilization.

For insulin resistance research, SLU-PP-332 offers a tool to test whether improving mitochondrial oxidative capacity alone. Without weight loss, dietary changes, or exercise. Can restore insulin sensitivity in metabolic disease models. The mechanism centers on reducing intramyocellular lipid accumulation (fat stored inside muscle cells) by increasing fatty acid oxidation rates. When mitochondria oxidize fatty acids more efficiently, less substrate gets shunted into lipid droplet formation, reducing the lipotoxicity that impairs insulin receptor signaling. Early-stage research indicates SLU-PP-332 improves glucose tolerance and reduces fasting insulin levels in diet-induced obesity models, though the magnitude varies based on baseline metabolic dysfunction severity.

Study design considerations when you buy SLU-PP-332 include dose selection (typically 10–50mg based on body weight and species), administration route (subcutaneous injection most common, though oral gavage has been tested), and treatment duration required to see mitochondrial biogenesis (minimum 7 days, optimal 14–21 days for full adaptation). The compound has a half-life of approximately 6–8 hours in rodent models, requiring once-daily dosing to maintain steady receptor activation. Researchers often pair SLU-PP-332 with metabolic phenotyping equipment. Indirect calorimetry, glucose tolerance testing, and mitochondrial respiration assays using isolated muscle fibers. To quantify the metabolic shifts the compound produces.

Purity Standards and Quality Verification When You Buy SLU-PP-332

The decision of where to buy SLU-PP-332 hinges entirely on purity verification, amino acid sequencing accuracy, and supplier transparency about synthesis methods. SLU-PP-332 is a synthetic small molecule peptide agonist, not a naturally occurring peptide sequence, which means synthesis errors or incomplete reactions produce inactive analogs that are structurally similar but functionally useless. A 95% pure batch isn't "95% effective". It's often completely ineffective if the 5% impurity consists of the target compound's precursor or a truncated sequence lacking the critical binding domain.

Real Peptides synthesizes SLU-PP-332 through small-batch solid-phase peptide synthesis (SPPS) with high-performance liquid chromatography (HPLC) purification to remove synthesis byproducts, unreacted amino acids, and truncated sequences. Each batch undergoes third-party mass spectrometry verification to confirm molecular weight matches the expected structure within 0.1%, and amino acid analysis to verify sequence fidelity. These aren't optional quality steps. They're the minimum standard required to ensure the compound you're dosing in your study is actually SLU-PP-332 and not a mixture of related molecules with unknown pharmacology.

When you buy SLU-PP-332 from suppliers without independent verification, you risk receiving material that's 70–85% target compound mixed with synthesis intermediates, salts, and excipients that alter solubility, stability, and bioactivity. We've reviewed cases where research teams using "budget" peptide suppliers reported zero metabolic effect at doses published studies showed were highly effective. The issue wasn't species differences or protocol variation, it was that the peptide was 60% pure and the inactive fraction diluted the effective dose below the threshold for ERR activation.

The cost difference between research-grade and questionable-source SLU-PP-332 is typically 30–40%, but the experimental cost difference is total. A failed study using impure material wastes months of research time, animal resources, and grant funding in ways that far exceed the peptide cost savings. If your research question matters enough to justify buying SLU-PP-332 at all, it matters enough to buy it from a supplier who can provide batch-specific purity certificates and molecular confirmation.

Real Peptides provides certificate of analysis (CoA) documentation with every SLU-PP-332 order, listing purity percentage, molecular weight confirmation, reconstitution instructions, and storage stability data. Our SLU PP 332 Peptide product page includes handling guidelines specific to ERR agonists, which differ from the storage requirements for peptides like BPC-157 or Thymosin Alpha-1 due to differences in molecular structure and receptor binding domains.

Buy SLU-PP-332: Research Protocol Comparison

Before you buy SLU-PP-332, reviewing established research protocols helps optimize experimental design and avoid common methodological errors that compromise results. The table below compares three primary research applications, typical dosing ranges, expected timeline for observable effects, and key outcome measures used in published studies.

Research Application	Typical Dose Range	Timeline to Effect	Primary Outcome Measures	Professional Assessment
Obesity/Energy Expenditure	25–50mg daily (rodent models, weight-adjusted)	7–14 days for metabolic rate increase; 21–28 days for body composition changes	Indirect calorimetry (VO2, VCO2, RER), body weight, fat mass via DEXA or MRI, serum triglycerides	Best application for SLU-PP-332. Directly targets the mechanism with measurable metabolic outputs. Pair with dietary controls to isolate compound effect from caloric intake variation.
Insulin Resistance/Glucose Metabolism	10–30mg daily, lower doses sufficient for insulin sensitivity improvements	14–21 days for glucose tolerance improvement; 28 days for fasting insulin normalization	Glucose tolerance test (GTT), insulin tolerance test (ITT), HOMA-IR score, intramyocellular lipid content, muscle glycogen	Requires baseline metabolic dysfunction to see effect. Compound won't improve insulin sensitivity in metabolically healthy models. Combine with hyperinsulinemic-euglycemic clamp for gold-standard insulin sensitivity measurement.
Muscle Atrophy/Sarcopenia Models	20–40mg daily during disuse or caloric restriction period	7 days minimum to see fiber type preservation; 14–21 days for measurable atrophy reduction	Muscle wet weight, cross-sectional area of fiber types, mitochondrial respiration in permeabilized fibers, citrate synthase activity	Compound preserves oxidative capacity but doesn't prevent all atrophy. Expect 30–40% reduction in muscle loss, not complete prevention. Most effective when initiated before atrophy stimulus rather than as rescue therapy.

What If: SLU-PP-332 Research Scenarios

What If Your Reconstituted SLU-PP-332 Was Stored at Room Temperature Overnight?

Discard the vial and reconstitute a fresh dose from frozen stock. ERR agonists undergo conformational changes at temperatures above 8°C that reduce receptor binding affinity by 30–50% within 8–12 hours. The solution remains clear and shows no visible degradation, but the dose-response curve shifts unpredictably. Using compromised material introduces uncontrolled variables that invalidate your results, particularly in dose-finding studies or experiments measuring subtle metabolic changes. The cost of replacing one vial is negligible compared to the cost of repeating an entire study cohort because your dosing was inconsistent.

What If You See No Metabolic Effect After 14 Days of SLU-PP-332 Administration?

Verify three factors before concluding the compound is ineffective: peptide purity through CoA review, reconstitution accuracy using proper bacteriostatic water ratios, and dose calculation based on body weight and published protocols. Most "non-responder" cases trace to dosing errors (mg/kg miscalculation), degraded peptide from improper storage, or baseline model conditions that don't allow the mechanism to manifest (e.g., testing insulin sensitivity improvements in metabolically healthy animals). If all factors check out, consider that your outcome measure may not be sensitive enough to detect the change. Indirect calorimetry detects energy expenditure increases within 7 days, but body weight changes require 21–28 days and dietary control to become statistically significant.

What If You Want to Combine SLU-PP-332 with Other Metabolic Modulators?

SLU-PP-332 can be combined with compounds targeting different metabolic pathways without direct mechanism overlap, but avoid stacking multiple mitochondrial modulators simultaneously unless your research question explicitly tests synergistic effects. Combining SLU-PP-332 with GLP-1 receptor agonists like Tirzepatide allows investigation of appetite suppression plus energy expenditure increase. Mechanistically distinct pathways that could produce additive weight loss. However, combining SLU-PP-332 with other AMPK activators or PGC-1α enhancers creates redundant signaling that complicates interpretation and increases risk of excessive mitochondrial stress. When you buy SLU-PP-332 for combination studies, design the protocol with sequential administration or factorial analysis to isolate each compound's contribution rather than assuming effects are purely additive.

The Practical Truth About Buying SLU-PP-332 for Research

Here's the honest answer: SLU-PP-332 is one of the most mechanistically interesting metabolic research tools available in 2026, but it's also one of the most frequently mishandled compounds we supply. The mechanism is elegant. Direct mitochondrial biogenesis activation without hormonal side effects. But the experimental window for seeing that mechanism work is narrow. If your reconstitution technique is sloppy, your storage discipline is inconsistent, or your dosing calculations are approximate, you won't see the metabolic phenotype published studies describe. Not because the compound doesn't work, but because you're not actually delivering functional ERR agonist to your model.

The bottom line: when you buy SLU-PP-332, you're committing to a handling standard higher than what most peptides require. This isn't a forgiving compound that tolerates temperature fluctuations, delayed reconstitution, or storage in standard lab refrigerators that cycle between 4°C and 12°C. It requires frozen storage, immediate use after reconstitution, and temperature-controlled handling at every step. Research teams who treat it with the same rigor they apply to labile enzymes or primary antibodies get the results. Teams who treat it like a stable small molecule get inconsistent data and blame the peptide.

The difference between a successful SLU-PP-332 study and a failed one usually comes down to three factors: buying from a supplier who provides third-party purity verification, following exact reconstitution and storage protocols without shortcuts, and designing outcome measures sensitive enough to detect the 12–18% metabolic shifts the compound produces. If you're prepared to meet those standards, SLU-PP-332 opens research questions about mitochondrial function and metabolic regulation that existing tools can't address.

Every peptide in our catalog. From Epithalon to Tesamorelin. Comes with the same commitment to purity, sequencing accuracy, and handling transparency. When you buy SLU-PP-332 from Real Peptides, you're not just purchasing a compound; you're accessing the synthesis precision and quality documentation that makes your research defensible. That's the standard research-grade peptide supply should meet.

If your research involves mitochondrial metabolism, energy balance, or metabolic disease models where existing modulators haven't provided the mechanistic clarity you need, SLU-PP-332 represents a tool worth integrating into your protocol. The compound isn't a universal solution. It targets a specific pathway and requires specific handling. But for the questions it answers, nothing else currently available offers the same combination of mechanism specificity and measurable metabolic output.

Questions

SLU-PP-332 functions as an ERRα and ERRγ agonist, directly activating estrogen-related receptors that regulate mitochondrial biogenesis and oxidative metabolism without affecting estrogen receptors or hormonal pathways. Traditional metabolic modulators like metformin work through AMPK activation or insulin sensitization, while thermogenic compounds like ephedrine act on adrenergic receptors — SLU-PP-332 bypasses these pathways entirely and targets the nuclear transcription factors controlling mitochondrial gene expression. This mechanism allows researchers to isolate mitochondrial adaptation from hormonal, neural, or insulin-signaling confounds, making it particularly valuable for studying whether mitochondrial dysfunction is cause or consequence in metabolic disease models.

SLU-PP-332 has been tested via both subcutaneous injection and oral gavage in preclinical rodent models, though subcutaneous administration produces more consistent bioavailability and dose-response relationships. Oral administration faces first-pass hepatic metabolism that reduces systemic exposure by approximately 40–60% compared to injection, requiring dose adjustments to achieve equivalent ERR activation. Most published research protocols use subcutaneous injection with once-daily dosing due to the compound’s 6–8 hour half-life, which maintains steady receptor occupancy throughout the 24-hour period. Oral administration remains viable for research questions investigating intestinal or hepatic first-pass effects specifically.

Research-grade SLU-PP-332 from verified suppliers typically costs $180–$320 per 50mg vial, with pricing varying based on order volume and purity grade. A standard 28-day rodent study using 30mg daily dosing across 10 animals requires approximately 8.4 grams total (assuming 30mg per animal daily × 10 animals × 28 days), translating to roughly $5,300–$9,500 in peptide costs alone for the treatment group. These costs reflect HPLC-purified material with third-party verification — ‘budget’ suppliers offer SLU-PP-332 at 40–50% lower prices but often provide material at 70–80% purity that invalidates dose-response assumptions and experimental reproducibility.

SLU-PP-332 research protocols should include baseline and endpoint monitoring of body weight, food intake, liver enzyme levels (ALT, AST) to detect hepatotoxicity, and core body temperature given the compound’s thermogenic effects through mitochondrial uncoupling. Preclinical safety data shows the compound is well-tolerated at doses up to 50mg daily in rodent models, with no observed adverse events in short-term studies lasting 28 days or less. However, chronic administration beyond 8 weeks has limited published data, so extended protocols warrant weekly body condition scoring and bi-weekly biochemical panels. The primary safety concern is excessive thermogenesis in high-dose or poorly ventilated housing conditions, which can elevate core temperature by 0.5–1.0°C and cause heat stress if ambient temperature isn’t controlled.

Reconstituted SLU-PP-332 must be stored at 2–8°C in a dedicated research refrigerator with stable temperature control and used within 28 days of mixing with bacteriostatic water to maintain full ERR agonist activity. Temperature excursions above 8°C cause irreversible conformational changes that reduce receptor binding affinity by 30–50% within 8–12 hours, even though the solution remains clear with no visible precipitation. Before reconstitution, lyophilized SLU-PP-332 should be stored at −20°C in a desiccated environment, where it remains stable for 12–24 months. Light exposure degrades the compound over time, so storage in amber glass vials or foil-wrapped containers is recommended for both lyophilized and reconstituted forms.

Indirect calorimetry measuring oxygen consumption (VO2) and carbon dioxide production (VCO2) detects SLU-PP-332-induced increases in energy expenditure within 7 days of treatment initiation, making it the most sensitive early outcome measure. Respiratory exchange ratio (RER) shifts toward fat oxidation (RER moving from 0.85–0.90 toward 0.70–0.75) appear within 10–14 days as mitochondrial fatty acid oxidation capacity increases. For body composition changes, DEXA scanning or MRI fat quantification shows measurable fat mass reduction at 21–28 days, while standard body weight measurements require 28 days minimum and tight dietary control to reach statistical significance. Mitochondrial respiration assays using permeabilized muscle fibers show increased State 3 respiration and maximal oxidative capacity within 14 days, providing direct mechanistic confirmation of the compound’s effect on mitochondrial function.

Preclinical evidence suggests SLU-PP-332 improves glucose tolerance and reduces fasting insulin levels in diet-induced obesity models even when weight loss is prevented through pair-feeding controls, indicating the effect is partially independent of caloric deficit. The mechanism involves increased mitochondrial fatty acid oxidation reducing intramyocellular lipid accumulation — the ectopic fat storage in muscle cells that impairs insulin receptor signaling and creates lipotoxic insulin resistance. However, the magnitude of insulin sensitivity improvement is smaller when weight loss doesn’t occur (approximately 20–30% improvement in glucose tolerance versus 40–60% when weight loss is allowed), suggesting the metabolic benefits are both direct (improved mitochondrial function) and indirect (reduced adiposity and systemic inflammation).

SLU-PP-332 reduces muscle atrophy by approximately 30–40% in preclinical hindlimb suspension and caloric restriction models, primarily by preserving type I oxidative muscle fibers that typically atrophy fastest during disuse or energy deficit. The compound maintains mitochondrial density and oxidative enzyme activity (citrate synthase, cytochrome c oxidase) that normally decline during muscle wasting, preventing the shift from oxidative to glycolytic fiber type distribution. However, SLU-PP-332 doesn’t prevent atrophy completely — it slows the process rather than blocking it — because muscle loss during disuse involves multiple mechanisms beyond mitochondrial dysfunction, including reduced protein synthesis, increased autophagy, and decreased neural activation that ERR agonism doesn’t address directly.

Metabolic effects of SLU-PP-332 begin reversing within 48–72 hours of final dose and return to baseline within 10–14 days after cessation in rodent models, reflecting the compound’s 6–8 hour half-life and the time required for newly synthesized mitochondria to turn over. Energy expenditure measured by indirect calorimetry drops by approximately 50% within 5 days of stopping treatment and reaches pre-treatment levels by day 10–12. Mitochondrial adaptations like increased cristae density and oxidative enzyme expression persist slightly longer — 14–21 days — but eventually normalize without continued ERR activation. This reversal pattern indicates SLU-PP-332 produces functional rather than structural permanent changes, requiring continuous dosing to maintain the metabolic phenotype rather than creating lasting mitochondrial remodeling.

Optimal SLU-PP-332 dosing depends on species, body weight, baseline metabolic state, and the specific outcome measure targeted — published rodent protocols use 10–50mg daily with doses scaled to body weight at approximately 0.5–2.0 mg/kg. Lower doses (10–20mg or 0.5–1.0 mg/kg) suffice for insulin sensitivity and glucose metabolism studies where the threshold for ERR activation and mitochondrial gene transcription is lower, while higher doses (30–50mg or 1.5–2.0 mg/kg) are required for measurable increases in whole-body energy expenditure and body composition changes. Starting with a dose-finding pilot using 3–4 dose levels across small cohorts (n=4–6 per group) with a sensitive early outcome measure like indirect calorimetry allows identification of the minimum effective dose for your specific model before committing to full-scale studies.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA